1. Home
  2. FTFT vs MBAI Comparison

FTFT vs MBAI Comparison

Compare FTFT & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Future FinTech Group Inc.

FTFT

Future FinTech Group Inc.

HOLD

Current Price

$2.20

Market Cap

11.2M

ML Signal

HOLD

Logo Check-Cap Ltd. Ordinary Share

MBAI

Check-Cap Ltd. Ordinary Share

N/A

Current Price

$1.47

Market Cap

10.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
FTFT
MBAI
Founded
N/A
2004
Country
United States
Israel
Employees
40
N/A
Industry
Business Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
11.2M
10.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FTFT
MBAI
Price
$2.20
$1.47
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
31.7K
23.7K
Earning Date
11-14-2025
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,665,719.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.96
$0.59
52 Week High
$19.99
$3.13

Technical Indicators

Market Signals
Indicator
FTFT
MBAI
Relative Strength Index (RSI) 71.90 N/A
Support Level $1.96 N/A
Resistance Level $2.71 N/A
Average True Range (ATR) 0.19 0.00
MACD 0.20 0.00
Stochastic Oscillator 75.19 0.00

Price Performance

Historical Comparison
FTFT
MBAI

About FTFT Future FinTech Group Inc.

Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and a cryptocurrency mining farm in the U.S. The company's reportable segments include asset management services, supply chain financing and trading, and others.

About MBAI Check-Cap Ltd. Ordinary Share

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Share on Social Networks: